A small-molecule/cytokine combination enhances hematopoietic stem cell proliferation via inhibition of cell differentiation

Table 2 Surface marker expression on day 7 after treatment with a cytokine combination

Groups	Medium content		CD34⁺ (%)	CD34⁺CD38^– (%)
Groups	Cytokines	Compounds	CD34⁺ (%)	CD34⁺CD38^– (%)
Cocktail	TSF	SR1 + VPA + C433	89.6 ± 8.6 ^A,B,C,D	79.6 ± 8.9 ^{a, b, c, d}
	6TSF		86.6 ± 11.2 ^A,E,F	76.2 ± 10.5 ^{a, e, f}
	3TSF		77.3 ± 10.8 ^A,G	68.5 ± 11.2 ^{a, g}
	36TSF		58.1 ± 2.1 ^A	55.6 ± 4.9 ^a
VC	TSF	DMSO	49.4 ± 18.2	44.1 ± 5.3
	6TSF		43.0 ± 12.5	38.0 ± 11.9
	3TSF		32.2 ± 3.2	32.2 ± 3.2
	36TSF		23.1 ± 0.5	21.1 ± 0.5

Data are shown as mean ± SD (n = 3)
^A p < 0.01, cocktail vs VC; ^B p < 0.05, TSF vs 6TSF; ^C p < 0.01, TSF vs 3TSF; ^D p < 0.001, TSF vs 36TSF; ^E p < 0.01, 6TSF vs 3TSF; ^F p < 0.01, 6TSF vs 36TSF; ^G p < 0.01, 3TSF vs 36TSF. For CD34⁺CD38^– rate analysis, ^a p < 0.01, cocktail vs VC; ^b p < 0.05, TSF vs 6TSF; ^c p < 0.001, TSF vs 3TSF; ^d p < 0.001, TSF vs 36TSF; ^e p < 0.01, 6TSF vs 3TSF; ^f p < 0.01, 6TSF vs 36TSF; ^g p < 0.05, 3TSF vs 36TSF
C433 CAY10433, DMSO dimethyl sulfoxide, SR1 stemregenin1, TSF TPO + SCF + Flt-3 L, 3TSF IL-3 + TPO + SCF + Flt-3 L, 6TSF IL-6 + TPO + SCF + Flt-3 L, 36TSF IL-6 + IL-3 + TPO + SCF + Flt-3 L, VC vehicle control, VPA valproic acid

ISSN: 1757-6512